GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Altman Z2-Score

Spectral AI (Spectral AI) Altman Z2-Score : -17.81 (As of May. 29, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Spectral AI Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Spectral AI has a Altman Z2-Score of -17.81, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Spectral AI's Altman Z2-Score or its related term are showing as below:

MDAI' s Altman Z2-Score Range Over the Past 10 Years
Min: -23.95   Med: -16.08   Max: 2.85
Current: -17.81

During the past 3 years, Spectral AI's highest Altman Z2-Score was 2.85. The lowest was -23.95. And the median was -16.08.


Spectral AI Altman Z2-Score Historical Data

The historical data trend for Spectral AI's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectral AI Altman Z2-Score Chart

Spectral AI Annual Data
Trend Dec21 Dec22 Dec23
Altman Z2-Score
- 2.85 -23.95

Spectral AI Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Altman Z2-Score Get a 7-Day Free Trial 2.85 -1.12 -16.08 -23.95 -17.81

Competitive Comparison of Spectral AI's Altman Z2-Score

For the Medical Devices subindustry, Spectral AI's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectral AI's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Spectral AI's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Spectral AI's Altman Z2-Score falls into.



Spectral AI Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Spectral AI's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-0.1697+3.26*-2.3247+6.72*-1.3382+1.05*-0.1158
=-17.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $15.48 Mil.
Total Current Assets was $14.88 Mil.
Total Current Liabilities was $17.51 Mil.
Retained Earnings was $-35.99 Mil.
Pre-Tax Income was -3.183 + -3.567 + -10.683 + -3.563 = $-21.00 Mil.
Interest Expense was -0.276 + 0 + 0 + 0 = $-0.28 Mil.
Total Liabilities was $17.51 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(14.884 - 17.511)/15.483
=-0.1697

X2=Retained Earnings/Total Assets
=-35.993/15.483
=-2.3247

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-20.996 - -0.276)/15.483
=-1.3382

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-2.028 - 0)/17.511
=-0.1158

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Spectral AI has a Altman Z2-Score of -17.81 indicating it is in Distress Zones.


Spectral AI  (NAS:MDAI) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Spectral AI Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Spectral AI's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectral AI (Spectral AI) Business Description

Traded in Other Exchanges
N/A
Address
2515 McKinney Avenue, Suite 1000, Dallas, TX, USA, 75201
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely and informed decision regarding the treatment of the patient's wound.
Executives
John Michael Dimaio 10 percent owner 6125 LUTHER LANE, DALLAS TX 75225
Michael Patrick Murphy director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Els 1960 Family, L.p. 10 percent owner 2323 VICTORY AVE., SUITE. 700, DALLAS TX 75219
Richard John Cotton director RUE DU VILLAGE 4, CHAMPERY V8 1874
Mellish Martin C.b. director 13 BERRILL FARMS LN, HANOVER NH 03755
Jeffrey Edward Thatcher officer: Chief Scientist 6659 ESCONDIDO ST, IRVING TX 75039
Nils Windler officer: Chief Financial Officer 8602 NAPA LANDING, SAN ANTONIO TX 78015
Wensheng Fan director, officer: CHIEF EXECUTIVE OFFICER 3320 SPRING MOUNTAIN DRIVE, PLANO TX 75025
Vincent S. Capone officer: GENERAL COUNSEL 1620 GRASSHOPPER LANE, LOWER GWYNEDD PA 19002
Nikolaos Pagoulatos officer: CHIEF OPERATING OFFICER 5122 IROQUOIS DR, FRISCO TX 75034
Xiaojia Cynthia Cai director 10 CELESTIAL WAY, NEWARK DE 19711
Heather Bellini director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Edmonds Franklin S. Jr. director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Rosecliff Acquisition Sponsor I Llc director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Erich Spangenberg 10 percent owner 73 595 EL PASEO, SUITE 2204, PALM DESERT CA 92260